Patient characteristics (N = 20)
| Characteristics . | Data . |
|---|---|
| Age, median (range), y | 63 (30-81) |
| Age >70 y | 7 (35) |
| Male/female ratio | 0.66 |
| ECOG-PS ≤1 | 20 (100) |
| High LDH serum level | 0 (0) |
| Extranodal marginal zone lymphoma | 20 (100) |
| HBV-HCV infection | 4 (20) |
| Eye | |
| Right | 6 (30) |
| Left | 7 (35) |
| Bilateral | 7 (35) |
| Prior treatment | |
| Doxycycline | 17 (85) |
| Doxycycline; clarithromycin | 1 (5) |
| Doxycycline; intravenous rituximab | 1 (5) |
| IV rituximab | 1 (5) |
| Refractory to prior line | 4 (20) |
| Characteristics . | Data . |
|---|---|
| Age, median (range), y | 63 (30-81) |
| Age >70 y | 7 (35) |
| Male/female ratio | 0.66 |
| ECOG-PS ≤1 | 20 (100) |
| High LDH serum level | 0 (0) |
| Extranodal marginal zone lymphoma | 20 (100) |
| HBV-HCV infection | 4 (20) |
| Eye | |
| Right | 6 (30) |
| Left | 7 (35) |
| Bilateral | 7 (35) |
| Prior treatment | |
| Doxycycline | 17 (85) |
| Doxycycline; clarithromycin | 1 (5) |
| Doxycycline; intravenous rituximab | 1 (5) |
| IV rituximab | 1 (5) |
| Refractory to prior line | 4 (20) |
Unless otherwise noted, all data are n (%).
ECOG-PS, Eastern Cooperative Oncology Group Performance Status; LDH, lactate dehydrogenase.